C12N 5/10
Cells modified by introduction of foreign genetic material
C12N5/10 (Cells modified by introduction of foreign genetic material) appears on 1,484 US grants and 2,438 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,484
- Published applications
- 2,438
- Assignees
- 1,270
- Inventors
- 5,631
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 5 | 0 |
| 1985 | 6 | 0 |
| 1986 | 7 | 0 |
| 1987 | 14 | 0 |
| 1988 | 8 | 0 |
| 1989 | 9 | 0 |
| 1990 | 16 | 0 |
| 1991 | 8 | 0 |
| 1992 | 17 | 0 |
| 1993 | 11 | 0 |
| 1994 | 7 | 0 |
| 1995 | 6 | 0 |
| 1996 | 15 | 0 |
| 1997 | 12 | 0 |
| 1998 | 14 | 0 |
| 1999 | 13 | 0 |
| 2000 | 6 | 0 |
| 2001 | 15 | 4 |
| 2002 | 6 | 23 |
| 2003 | 9 | 21 |
| 2004 | 2 | 20 |
| 2005 | 4 | 22 |
| 2006 | 10 | 20 |
| 2007 | 6 | 15 |
| 2008 | 8 | 14 |
| 2009 | 13 | 26 |
| 2010 | 5 | 33 |
| 2011 | 3 | 42 |
| 2012 | 15 | 30 |
| 2013 | 26 | 46 |
| 2014 | 37 | 64 |
| 2015 | 54 | 60 |
| 2016 | 56 | 79 |
| 2017 | 74 | 144 |
| 2018 | 65 | 201 |
| 2019 | 90 | 227 |
| 2020 | 126 | 206 |
| 2021 | 123 | 209 |
| 2022 | 145 | 179 |
| 2023 | 127 | 156 |
| 2024 | 104 | 200 |
| 2025 | 113 | 232 |
| 2026 | 71 | 165 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- FOXM1-derived peptide, and vaccine including same29 Sep 2026US 12,747,265 B2Oncotherapy Science, Inc.
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell8 Sep 2026US 12,729,372 B2Changen Therapeutics (Shanghai) Co., Ltd.
- Cell lines for high level production of protein selected for rapid proliferation1 Sep 2026US 12,723,244 B2CHO Plus, Inc.
- Neurodegenerative and amyotrophic model animal25 Aug 2026US 12,714,076 B2Tokyo Metropolitan Institute of Medical Science
- Immune inducer3 Sep 2026US 2026/0258100 A1Toray Industries, Inc.
- Method and drug for treating cancer by joint use of nkg2d chimeric antigen receptor and pd1 inhibitor27 Aug 2026US 2026/0248853 A1Daren Biotech Limited
- Universal donor cells27 Aug 2026US 2026/0248859 A1Crispr Therapeutics AG
- Tcr molecule targeting kras g12v mutation, cell, and uses thereof27 Aug 2026US 2026/0250388 A1Beijing Dcty Biotech Co., Ltd.
- Method for producing primed pluripotent stem cells27 Aug 2026US 2026/0250631 A1Kyoto University
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998
- Transgenic non-human animals for producing heterologous antibodies679US 5,814,318 AGenPharm International, Inc. · 1998